Skip to main content
https://pbs.twimg.com/media/FhLirauXoAADG9v.jpg
Spiera et al. Resolution PMR in SAPHYR trial IL-6i sarilumab. Week 52, 81% vs 57% with no signs/symptoms More in PBO arm needed rescue GCs 58.6% vs 32.2% @RheumNow #ACR22 Abstr#1543 https://t.co/3Sr8aB2SpC https://t.co/mjuzNFWcdn
Richard Conway
13-11-2022
×